11th week of 2016 patent applcation highlights part 22 |
Patent application number | Title | Published |
20160075684 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-III - The present invention relates to chemical compounds useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (α7 nAChR). | 2016-03-17 |
20160075685 | Novel Crystal Form - A novel crystalline form of a compound is disclosed. | 2016-03-17 |
20160075686 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS - The invention provides novel compounds having the general formula (I) | 2016-03-17 |
20160075687 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS - The invention provides novel compounds having the general formula (I) | 2016-03-17 |
20160075688 | NEW 3,4-DIHYDRO-2H-ISOQUINOLINE-1-ONE AND 2,3-DIHYDRO-ISOINDOL-1-ONE COMPOUNDS - The invention provides novel compounds having the general formula (I) | 2016-03-17 |
20160075689 | POLYMERASE, ENDONUCLEASE, AND HELICASE INHIBITORS AND METHODS OF USING THEREOF - Inhibitors of DNA damage polymerases, endonucleases, and helicases are provided. In particular, compounds comprising Formula (I) are described. | 2016-03-17 |
20160075690 | SUBSTITUTED 1-BENZYLQUINOXALIN-2(1H) ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYLCHOLINE RECEPTOR M1 - The invention relates to substituted 1-benzylquinoxalin-2(1H)-one analogs, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChR M1); methods for making the compounds; pharmaceutical compositions; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction. | 2016-03-17 |
20160075691 | 4,5- DIHYDROPYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY - The present invention relates to 4,5-dihydropyrazole derivatives of the formula (I) | 2016-03-17 |
20160075692 | Indazole Ureas and Method of Use - Compounds of formula (I) | 2016-03-17 |
20160075693 | AVANAFIL PREPARATION METHOD - Disclosed is a method for preparing avanafil (I) by using cytosine as the starting material. The preparation steps comprise: using cytosine as the raw material, and enabling the cytosine to react with side chain 3-chlorine-4-methoxybenzyl halogen, N-(2-methylpyrimidine) methanamide and S-hydroxymethyl pyrrolidine, to prepare the target product avanafil (I). For the preparation method, the raw material is easily obtained, and the process is simple, economical, and environmentally friendly, so the method meets the requirement of industrial boost. | 2016-03-17 |
20160075694 | A PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE - The present invention relates to the compound (2R,2′R)-bis(((((tetrahydro-2H-pyran-4-yl)oxy)carbonyl)oxy)methyl) 1,1′-adipoylbis(pyrrolidine-2-carboxylate) of formula (I), pharmaceutical compositions comprising the same and the use of the same for treatment of diseases or disorders wherein depletion of serum amyloid P component (SAP) would be beneficial, including amyloidosis, Alzheimer's disease, type 2 diabetes mellitus and osteoarthritis. | 2016-03-17 |
20160075695 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS - This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R | 2016-03-17 |
20160075696 | SUBSTITUTED 2-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS - The present invention is directed to compounds of Formula I: | 2016-03-17 |
20160075697 | HETEROCYCLIC SUBSTITUTED-3-HETEROARYLIDENYL-2-INDOLINONE DERIVATIVE - Disclosed is a compound represented by formula (1) or a pharmacologically acceptable salt thereof. (In the formula, R | 2016-03-17 |
20160075698 | FLUORINATED INTEGRIN ANTAGONISTS - The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof. | 2016-03-17 |
20160075699 | 3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER - The present invention relates to compounds of formula (I) which are inhibitors of NF- | 2016-03-17 |
20160075700 | YELLOW REDUCED PYRROLOQUINOLINE QUINONE CRYSTAL AND METHOD OF PRODUCING THE SAME, AND FOOD, PHARMACEUTICAL, GEL, COMPOSITION AND METHOD OF PRODUCING COMPOSITION - A yellow reduced pyrroloquinoline quinone crystal having a solubility in water of 0.040 to 0.20 (mg/mL). | 2016-03-17 |
20160075701 | 2-(1H-INDAZOL-3-YL)-1H-IMIDAZO[4,5-C]PYRIDINE AND THERAPEUTIC USES THEREOF - Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states. | 2016-03-17 |
20160075702 | NEW PYRIDOPYRIMIDINES DERIVATIVES COMPOUNDS - The present invention describes new pyridopyrimidine derivatives compounds with structure represented by General Formula (I): | 2016-03-17 |
20160075703 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES - This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives having the Formula I: | 2016-03-17 |
20160075704 | NOVEL SUBSTITUTED SPIROCYCLES - This invention relates to a compound of formula I | 2016-03-17 |
20160075705 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA - Compounds that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compounds also are disclosed. | 2016-03-17 |
20160075706 | COMPOUNDS AS MODULATORS OF ROR GAMMA - The present invention encompasses compounds of the formula (I) | 2016-03-17 |
20160075707 | METHODS OF PREPARING TOLL-LIKE RECEPTOR MODULATORS - The present invention provides methods of preparing 4-amino-2-butoxy-8-(3-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropteridin-6(5H)-one and related compounds. | 2016-03-17 |
20160075708 | ANTI-ANGIOGENESIS COMPOUND, INTERMEDIATE AND USE THEREOF - Disclosed are an anti-abnormal proliferation of angiogenesis compound represented by formula I, use and intermediate thereof. The compound has good effect against abnormal proliferation of angiogenesis, and the activity of the compound is produced by inhibiting VEGFR2. The compound can be used for treating diseases, such as wet macular degeneration, inflammation, malignant tumor and the like, caused by abnormity of angiogenesis and protein kinases such as VEGFR2, FGFR2 and the like. | 2016-03-17 |
20160075709 | PYRAZINO[1,2-a]INDOLE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS - The invention refers to compounds of general formula (I) | 2016-03-17 |
20160075710 | PYRIDAZINONE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS - Compounds of formula (I) described herein inhibit phosphoinositide 3-kinases (PI3K) and useful for the treatment of disorders associated with PI3K enzymes. | 2016-03-17 |
20160075711 | COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE - The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of IDO, and for the treatment of IDO-related disorders. | 2016-03-17 |
20160075712 | HETEROCYCLIC COMPOUNDS AND USES THEREOF - Heterocyclic compounds of formula (I), pharmaceutical compositions containing such a compound and their therapeutic uses. | 2016-03-17 |
20160075713 | PYRROLOPYRIMIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS - Disclosed are chemical entities of formula I: | 2016-03-17 |
20160075714 | Antimicrobial Potentiators - Novel compounds are disclosed having the structure of Formula I: | 2016-03-17 |
20160075715 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): | 2016-03-17 |
20160075716 | POLYMERIC MATERIALS - The present invention relates to a polymer comprising as part of its polymer backbone a moiety of Formula (II): | 2016-03-17 |
20160075717 | ACRYLIC COMPOUND HAVING TETRAOXASPIRO BACKBONE FOR RADIATION CURING COMPOSITIONS(CORRECTED TITLE) - Disclosed is a process for obtaining an acrylic compound haying a tertaoxaspiro backbone and at least one acrylic unsaturation. Said compound is in embodiments an acrylate, a methacrylate or a crotonate of an alkoxylated, such as an ethoxylated, a propoxylated and/or a butoxylated 2,4,8,10-tetraoxaspiro[5.5]undecane-3, 9- dialkanol. | 2016-03-17 |
20160075718 | Organic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device, and Lighting Device - An organic compound represented by a general formula (G1). | 2016-03-17 |
20160075719 | THERAPEUTIC THIOPHENE-, FURAN-, AND PYRIDINE-FUSED AZOLOPYRIMIDIN-5-(6H)-ONES - Described herein are compounds of Formula I and Formula II, methods of their synthesis, compositions comprising the compounds, and use of the compounds and compositions in treating numerous diseases and disorders, including cognitive deficits associated with CNS diseases and disorders. | 2016-03-17 |
20160075720 | MK2 INHIBITORS AND USES THEREOF - The present invention provides compounds, compositions thereof, and methods of using the same. | 2016-03-17 |
20160075721 | TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS - The present disclosure relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer. | 2016-03-17 |
20160075722 | Antibacterial Biaromatic Derivatives - The invention relates to antibacterial compounds of formula I (I) wherein R is H, cyano, alkoxy, cyanomethoxy, cycloalkylmethoxy, hydroxyalkoxy, alkoxyalkoxy, alkoxycarbonyl, 2-ethoxy-2-oxoethoxy, 2-(methylamino)-2-oxoethoxy, (1-cyanocyclobutyl)methoxy, 3-hydroxy-pyrrolidin-1-yl or 3,4-dihydroxycyclopentyl)methoxy; U | 2016-03-17 |
20160075723 | PROCESS FOR THE PREPARATION OF AMINOARYL- AND AMINOHETEROARYL BORONIC ACIDS AND ESTERS - The present invention relates to a process for the preparation of aminoaryl- and aminoheteroaryl boronic acids and esters thereof of formula (I) in high yield. The claimed process uses diarylketal formula (V) to generate an arylbromide of formula (III) in which the amino-group is protected as bisarylmethylidenimino-group, which is then transformed into a formula (I) compound. | 2016-03-17 |
20160075724 | CETP Inhibitors - Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: | 2016-03-17 |
20160075725 | COLORED CHARGED SILSESQUIOXANES - The present invention provides salts of a cation and an anion, wherein the cation comprises
| 2016-03-17 |
20160075726 | TAMOXIFEN DERIVATIVES FOR TREATMENT OF NEOPLASTIC DISEASES, ESPECIALLY WITH HIGH HER2 PROTEIN LEVEL - The subject of the invention are new mitochondrially targeted E/Z isomers of aliphatic triphenylphosphonium derivatives of tamoxifen where the aliphatic chain is alkyl or alkenyl, and their corresponding tertiary amine salts and/or their mixture (MitoTAX). Alkyl triphenylphosphonium derivatives of tamoxifen have the general formula (I), where n=8 to 12 and where Z is selected from the group of organic salts or inorganic salts. Alkenyl triphenylphosphonium derivatives of tamoxifen have the general formula IA, where n=6 to 10 and where Z has the above mentioned meaning. These compounds are applicable for the treatment of neoplastic disease, especially those with high HER2 protein levels. The drug for the treatment of neoplastic diseases according to the invention contains at least one E/Z isomer of aliphatic triphenylphosphonium derivatives of tamoxifen of the general formula (I) and/or IA or their corresponding salts of tertiary amine. | 2016-03-17 |
20160075727 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS - The present invention provides a compound of Formula I: | 2016-03-17 |
20160075728 | Chiral Imidazolium Salts for Asymmetric Catalysis - Planar chiral N-heterocyclic carbenes that incorporate an iron sandwich complex into the NHC framework are disclosed for use in organocatalytic and transition metal-catalyzed reactions. | 2016-03-17 |
20160075729 | SYNTHESIS OF SIALYLATED/FUCOSYLATED HUMAN MILK OLIGOSACCHARIDES - An achemo-enzymatic synthesis of oligosaccharides of formula 1 is presented wherein R is selected from —OH, —N3 and —OR6 wherein R6 is selected from allyl optionally substituted by one or more methyl, propargyl optionally substituted by one or more methyl, 2-trimethylsilyl-ethyl, —(CH2)n—NH2 and —(CH2)n—N3 wherein integer n is to 10, preferably 2 or 3, R is selected from sialyl moiety, —SO3H and —CH(R)—COOH wherein R is selected from H, alkyl and benzyl, R2 is selected from H and fucosyl, R3 is selected from H and sialyl, R4 is selected from H and fucosyl, provided that at least one of R3 and R4 is H, and A is a divalent carbohydrate linker, having important biological activities and significant commercial value for the pharmaceutical and food industry. | 2016-03-17 |
20160075730 | NEW MORPHOLINYL ANTHRACYCLINE DERIVATIVES - The present invention relates to new morpholinyl anthracycline derivatives which have cytotoxic activity and are useful in treating diseases such as cancer, cellular proliferation disorders and viral infections. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising them and methods of treating diseases utilizing such compounds or the pharmaceutical compositions containing them. | 2016-03-17 |
20160075731 | URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE - This disclosure relates to uridine nucleoside derivatives, compositions comprising therapeutically effective amounts of those nucleoside derivatives and methods of using those nucleoside derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P | 2016-03-17 |
20160075732 | RADICAL ORBITAL SWITCHING - Described herein are distonic radical anion species of formula (I): RAD-L-NEG; wherein RAD is a group comprising a radical; NEG is a group comprising an anion, which is capable of bonding to a proton or other cation; L is a linker that links NEG to RAD; and the radical of RAD is not π-conjugated to the anion of NEG. | 2016-03-17 |
20160075733 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | 2016-03-17 |
20160075734 | PEPTOID AFFINITY LIGANDS - Compounds of Formulas I: | 2016-03-17 |
20160075735 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME - Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity. | 2016-03-17 |
20160075736 | Process for the Preparation of Bortezomib Mannitol Ester - A novel and improved process for preparation of bortezomib mannitol ester is derived, which process avoids excessive use of solvents, involves convenient, industrially feasible and economical techniques, and provides improvements in purity over processes known in the art. | 2016-03-17 |
20160075737 | SYNTHETIC ANTI-INFLAMMATORY PEPTIDES AND USE THEREOF - The present invention is directed to synthetic anti-inflammatory peptides and use thereof in the treatment and prevention of inflammatory and fibrotic conditions. Specifically, the invention relates in some embodiments to short isolated peptides having the amino acid sequence Phe-Lys-Glu (FKE), Tyr-Lys-Glu (YKE) or comprising a plurality of these sequences that may be flanked by Ala/Gly (A/G) linkers. The invention further relates in some embodiments to methods for inhibiting scar formation and for treating and alleviating IL-10 dependent conditions. | 2016-03-17 |
20160075738 | COMPOUNDS USEFUL IN THE TREATMENT AND/OR CARE OF THE SKIN AND THEIR COSMETIC OR PHARMACEUTICAL COMPOSITIONS - Compounds of general formula (I): their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, cosmetic and/or pharmaceutical compositions which contain them and their use in medicine, and in the treatment and/or care of the skin, particularly in the aging and photoaging of the skin, and more particularly for the treatment and/or prevention of wrinkles and/or stretch marks. | 2016-03-17 |
20160075739 | PEPTIDE FOR INDUCING MAST CELL-SPECIFIC APOPTOSIS AND USE THEREOF - A peptide according to the present invention can perform a function identical or similar to the function of natural CTLA-4 and has an excellent degree of skin penetration due to a small size. The peptide according to the present invention effectively binds to antigen presenting cell surface proteins (CD80 and CD86) to inhibit activity of T cells and thus is capable of inhibiting the expression of inflammatory cytokines (for example, IL-2 and IFN-γ). As a result, a composition comprising the peptide according to the present invention exhibits excellent effects in terms of preventing, treating, or improving Th1-mediated immune diseases. Therefore, the superior activity and stability of the peptide according to the present invention can be useful when applied to medicine, quasi-drugs, and cosmetics. | 2016-03-17 |
20160075740 | ANTIFUNGAL AGENTS AND USES THEREOF - The invention features echinocandin class compounds. The compounds can be useful for the treatment of fungal infections. | 2016-03-17 |
20160075741 | CYCLOSPORINE ANALOGUE MIXTURES AND THEIR USE AS IMMUNOMODULATING AGENTS - The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISA | 2016-03-17 |
20160075742 | HUMAN ADAPTATION OF H3 INFLUENZA - The present invention provides, among other things, technologies and methodologies for detection, treatment, and/or prevention of influenza transmission and/or infection. The present invention also provides technologies for monitoring influenza variants for their potential to present a pandemic risk to humans. | 2016-03-17 |
20160075743 | Methods and Materials for Encapsulating Proteins - The invention provides a method for encapsulating a protein of interest, the method comprising the step of expressing a fusion protein comprising an N-terminal region of a rearrangement hot spot (RHS)-repeat-containing protein fused to the protein of interest. The invention further provides applications for the encapsulation, release and delivery of the protein of interest. The invention also encompasses the encapsulated protein of interest and compositions comprising the encapsulated protein of interest. The invention also provides uses of the encapsulated protein of interest, optionally after release from encapsulation, to control pests. The encapsulated protein of interest may for example be produced via expression in a plant to control a pest of the plant, such as an insect pest. | 2016-03-17 |
20160075744 | DNA-BINDING PROTEIN USING PPR MOTIF, AND USE THEREOF - The object of the present invention is to, by analyzing PPR proteins that act to bind to DNA with a prediction that RNA recognition rules of PPR motifs can also be used for recognition of DNA, find a PPR protein showing such a characteristic. According to the present invention, it was revealed that, with a protein that can bind in a DNA base-selective manner or a DNA base sequence-specific manner, which contains one or more, preferably 2 to 30, more preferably 5 to 25, most preferably 9 to 15, of PPR motifs having a structure of the following formula 1 (wherein, in the formula 1, Helix A is a part that can form an α-helix structure; X does not exist, or is a part consisting of 1 to 9 amino acids; Helix B is a part that can form an α-helix structure; and L is a part consisting of 2 to 7 amino acids), and having a specific combination of amino acids corresponding to a DNA base or DNA base sequence as amino acids of three positions of No. 1 A.A., No. 4 A.A., in Helix A of the formula 1 and No. “ii” (-2) A.A. contained in L of the formula 1, the aforementioned object could be achieved. | 2016-03-17 |
20160075745 | MITOCHONDRIAL PROTEINS CONSTRUCTS AND USES THEREOF - Disclosed are novel fusion protein constructs comprising a functional mitochondrial protein, that can enter mitochondria within intact cells. Further disclosed are methods of treating mitochondrial disorders by the disclosed fusion proteins and compositions therefor. | 2016-03-17 |
20160075746 | TAILORING MULTIVALENT INTERACTIONS OF BIOPOLYMERS WITH A POLYPROLINE SCAFFOLD - A glycopeptide, comprising a polyproline backbone and one or more carbohydrate molecules. | 2016-03-17 |
20160075747 | METHOD FOR PRODUCING PROTEIN - It has been believed that promoting the assembly of polysomes composed of many ribosomes attached to mRNA is very effective for highly efficient protein synthesis. However, the mechanism for p180 protein's capability of promoting polysome formation has been yet to be elucidated. | 2016-03-17 |
20160075748 | Aquaporin-4 Peptide Compositions and Methods of Use - The present disclosure provides human Aquaporin 4 (AQP4) peptides and peptides having homology to human Aquaporin 4 (AQP4) peptides. Also provided herein are methods for using human AQP4 peptides and peptides homologous to human AQP4 peptides for diagnosing and/or treating Neuromyelitis Optica. | 2016-03-17 |
20160075749 | ANTIMICROBIAL PEPTIDE - The disclosure relates to antimicrobial peptides, pharmaceutical compositions comprising the peptides and to uses thereof for treatment or prevention of microbial, bacterial, fungal, viral and parasitic infection. | 2016-03-17 |
20160075750 | Production of TSG-6 Protein - A method of producing a protein or polypeptide, such as, for example, TSG-6 protein, or a biologically active fragment, derivative or analogue thereof, by introducing into mammalian cells a polynucleotide encoding the biologically active protein or polypeptide or biologically active fragment, derivative, or analogue thereof. The cells then are suspended in a protein-free medium that includes at least one agent that suppresses production of hyaluronic acid, hyaluronan, or a salt thereof by the cells. The cells are cultured for a time sufficient to express the biologically active protein or polypeptide or biologically active fragment, derivative or analogue thereof. The biologically active protein or polypeptide, or fragment, derivative, or analogue thereof then is recovered from the cells, such as, for example, by recovering the protein or polypeptide secreted by the cells from the cell culture medium. | 2016-03-17 |
20160075751 | Glycoprotein Hormone Long-Acting Superagonists - This invention provides long-acting, superactive analogs of glycoprotein hormones demonstrating enhanced bioactivity both in vitro and in vivo as compared to wild type counterparts. The analogs are particularly useful for treating subjects showing low receptor expression or poor receptor responsiveness, and for the treatment of any condition associated with glycoprotein hormone activity. | 2016-03-17 |
20160075752 | B-TYPE PLEXIN ANTAGONISTS AND USES THEREOF - The present invention concerns the field of cancer therapy. In particular, it relates to an antagonist of a B-type plexin which prevents the interaction of the B-type plexin with ErbB-2 for use as a medicament, in particular, for treating metastasizing cancer. The present invention also contemplates a method for identifying an antagonist which prevents the interaction of a B-type plexin with ErbB-2. Finally, the invention provides for a polynucleotide encoding a B-type plexin polypeptide which lacks a functional intracellular domain and the said polypeptide. | 2016-03-17 |
20160075753 | MODULATION OF REGULATORY T CELL FUNCTION VIA PROTEIN KINASE C-eta - Compounds, uses and methods for modulating an immune response are provided. In particular, modulating the interaction of PKCη with CTLA-4 can modulate an immune response. For example, modulating activity or expression of PKCη, and/or modulating activity or expression of CTLA-4, can be used to modulate interaction of PKCη with CTLA-4, thereby modulating an immune response. | 2016-03-17 |
20160075754 | CHIMERIC POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME - A plant produced chimeric polypeptide is provided. The plant produced chimeric polypeptide comprising: | 2016-03-17 |
20160075755 | IMMUNOSUPPRESSIVE TGF- SIGNAL CONVERTER - Embodiments of the disclosure concern cell therapy methods and compositions utilizing cells expressing at least a chimeric TGFβ receptor including the exodomain of a TGFβII receptor and an endodomain that is not from TGFβ receptor, thereby converting the negative signal of TGFβ for T cell proliferation into a T cell activation signal. In at least certain aspects, cells harboring the chimeric TGFβ receptor also harbor one or more chimeric antigen receptors. | 2016-03-17 |
20160075756 | ALBUMIN VARIANTS - The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 2016-03-17 |
20160075757 | ALBUMIN VARIANTS - The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 2016-03-17 |
20160075758 | ALBUMIN VARIANTS - The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 2016-03-17 |
20160075759 | ALBUMIN VARIANTS - The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 2016-03-17 |
20160075760 | ALBUMIN VARIANTS - The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 2016-03-17 |
20160075761 | ALBUMIN VARIANTS - The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 2016-03-17 |
20160075762 | ALBUMIN VARIANTS - The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 2016-03-17 |
20160075763 | ALBUMIN VARIANTS - The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin. | 2016-03-17 |
20160075764 | OPTIMAL INTERSTRAND BRIDGE FOR COLLAGEN MIMICS - Novel collagen-mimetic peptides are disclosed comprising the formula (Xaa-Yaa-Gly) | 2016-03-17 |
20160075765 | MODIFIED COLLAGEN MOLECULES - This invention relates to modified collagen molecules, in particular, modified collagen-glycosaminoglycan composites. This invention also provides methods for stabilizing collagen molecules and uses of these collagen molecules. | 2016-03-17 |
20160075766 | METHOD FOR PRODUCING ANTIBODIES USING OVINE B-CELLS AND USES THEREOF - Herein is reported a cultivation system for cultivating a pool of ovine B-cells or single deposited ovine B-cells in the presence of phorbol myristate acetate (PMA). | 2016-03-17 |
20160075767 | CAPPING MODULES FOR DESIGNED ANKYRIN REPEAT PROTEINS - Improved N-terminal capping modules for designed Ankyrin repeat proteins (DARPins) conferring improved thermal stability to the DARPins are described, as well as nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases. | 2016-03-17 |
20160075768 | ADJUVANT THERAPY FOR STAPHYLOCOCCAL INFECTION WITH ENTEROTOXIN SPECIFIC MABS - Antibodies to SEB, fragments thereof, and compositions comprising such are provided. Therapies for staphylococcal infection are provided, as well as assays for identifying additional agents useful in such therapies. An isolated antibody, or an isolated antigen-binding fragment of an antibody, is provided which antibody or antigen-binding fragment binds to staphylococcal enterotoxin B (SEB) and which antibody or antigen-binding fragment comprises a heavy chain variable CDR3 comprising the sequence RIYYGNNGGVMDY (SEQ ID NO:30); ARTAGLLAPMDY (SEQ ID NO:31); ARDTMRKCYCELKLKPPAEHPGPA (SEQ ID NO:32) or VRDL YGDYVGRY A Y (SEQ ID NO:48). | 2016-03-17 |
20160075769 | AGROCHEMICAL COMPOSITIONS COMPRISING ANTIBODIES BINDING TO SPHINGOLIPIDS - The present invention relates to agrochemical and biological control compositions for combating pests, more specifically plant pests, comprising at least one polypeptide, which specifically binds to a pest. The invention further provides methods for protecting or treating a plant or a part of a plant from an infection or other biological interaction with a plant pathogen, at least comprising the step of applying directly or indirectly to a plant or to a part of a plant, an agrochemical composition, under conditions effective to protect or treat a plant or a part of a plant against a infection or biological interaction with a plant pathogen. Further provided are methods for producing such agrochemical compositions and formulations, to polypeptides with a specific pesticidal activity comprised within an agrochemical formulation, to nucleic acids encoding such polypeptide and to plants comprising chimeric genes comprising such nucleic acids. | 2016-03-17 |
20160075770 | Composition with Reduced Immunogenicity - The present invention relates to a composition comprising polyclonal antibodies directed against human cells, wherein the said polyclonal antibodies are devoid of a first antigenic determinant selected in a group comprising (i) N-glycol-neuraminic acid (Neu5Gc) and (ii) α-1,3-galactose and its use as a medicament | 2016-03-17 |
20160075771 | Methods for Treating Neoplasia - The invention provides therapeutic methods featuring the use of chimeric human/mouse antibodies for the treatment of neoplasia. | 2016-03-17 |
20160075772 | Treatment of Fibrodysplasia Ossificans Progressiva - Methods for treating Fibrodysplasia Ossificans Progressiva (FOP) are provided. Such methods involve administering to a subject having FOP an effective regime of an activin receptor type 2A (ACVR2A) and/or an activin receptor type 2B (ACVR2B) antagonist or an activin receptor type 1 (ACVR1) antagonist. Antagonists include fusion proteins of one or more extracellular domains (ECDs) of ACVR2A, ACVR2B and/or ACVR1 and the Fc domain of an immunoglobulin heavy chain, and antibodies against ACVR2A, ACVR2B, ACVR1 or Activin A. | 2016-03-17 |
20160075773 | MONOCLONAL ANTIBODIES AGAINST THE RGM A PROTEIN FOR USE IN THE TREATMENT OF RETINAL NERVE FIBER LAYER DEGENERATION - The present application describes RGM A binding proteins, particularly monoclonal antibodies, and in particular CDR grafted, humanized versions thereof, which have the ability to bind to RGM A and prevent binding of RGM proteins to RGM A receptor and other RGM A binding proteins, and therefore neutralize the function of RGM A, for use in the treatment of retinal nerve fiber layer (RNFL) degeneration as well as methods of therapeutically or prophylactically treating a mammal against RNFL degeneration. | 2016-03-17 |
20160075774 | ANTI-SERUM ALBUMIN BINDING VARIANTS - The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-14, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts. | 2016-03-17 |
20160075775 | TREATMENT OF TRAUMATIC BRAIN INJURY USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID - Methods are provided for treating neurotrauma, for example, traumatic brain injury (TBI), using antibodies and antibody fragments that bind lysophosphatidic acid (LPA). Such treatment may result in functional locomotor recovery in subjects so treated, as well as reducing the size of a brain infarct in subjects having or suspected of having sustained neurotrauma such a TBI. | 2016-03-17 |
20160075776 | Compositions and Methods for Controlled Release of Agents - This invention discloses reservoirs, such as implants for delivering therapeutic agents, particularly large molecules such as proteins and antibodies. The reservoirs may comprise a porous silicon-based carrier material impregnated with the therapeutic agent. The reservoir may be used in vitro or in vivo to maintain an equilibrium concentration of a therapeutic agent over an intended period of time such as over multiple days, weeks, months, or years. Additionally, the reservoir may be reloaded with additional therapeutic agent. These reservoirs may be used for treating or preventing conditions of a subject such as chronic diseases. | 2016-03-17 |
20160075777 | ANTI-IL-4/ANTI-IL-13 BISPECIFIC ANTIBODY FORMULATIONS - The present invention provides stable pharmaceutical antibody formulations, including lyophilized formulations, comprising an anti-IL-4/anti-IL-13 bispecific antibody and a buffering system, wherein the pH of the formulation is about pH 7, and wherein the formulation has a low salt concentration in order to reduce the ionic strength of the formulation. The formulations may, optionally, further comprise a non-ionic surfactant, a sugar, and/or a non-ionic stabilizing agent. The formulations can be used in the treatment of various diseases. | 2016-03-17 |
20160075778 | Anti-Glucagon Antibodies and Uses Thereof - The present invention provides antibodies that bind to glucagon and methods of using the same. According to certain embodiments, the antibodies of the invention bind human GCG with high affinity. The antibodies of the invention may be fully human antibodies. The antibodies of the invention are useful for the treatment of various diseases or disorders characterized by elevated blood glucose levels, as well as other GCG-related disorders. | 2016-03-17 |
20160075779 | DLL3 MODULATORS AND METHODS OF USE - Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided. | 2016-03-17 |
20160075780 | ANTIBODY AGAINST HUMAN PROSTAGLANDIN E2 RECEPTOR EP4 - It is an object of the present invention to provide an antibody that binds to a human PGE | 2016-03-17 |
20160075781 | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof - Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to human folate receptor 1 are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided. | 2016-03-17 |
20160075782 | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1) - The present disclosure provides isolated monoclonal antibodies particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies. | 2016-03-17 |
20160075783 | ANTIBODIES DIRECTED AGAINST PROGRAMMED DEATH-1 (PD-1) - The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that bind to a programmed death-1 (PD-1) protein. The invention provides a PD-1-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides related vectors, compositions, and methods of using the PD-1-binding agent to treat a cancer or an infectious disease. | 2016-03-17 |